s_150324_6a
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- fusion
- YAP1_MAMLD1
- e1_e2
- E2
- umap1_2d
- -7.844813573
- umap2_2d
- 1.025908091
- umap1_3d
- 0.086456213
- umap2_3d
- 4.123979396
- umap3_3d
- 1.579590287
- dataset
- EPN-Heidelberg
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.480
- OXIDATIVE_PHOSPHORYLATION+0.400
- DNA_REPAIR+0.370
- PROTEIN_SECRETION+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.200
- MYC_TARGETS_V2+0.160
- NOTCH_SIGNALING+0.160
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160
- E2F_TARGETS+0.110
- HEME_METABOLISM+0.110
Top 10 suppressed
- APICAL_SURFACE-0.470
- ANGIOGENESIS-0.460
- IL6_JAK_STAT3_SIGNALING-0.460
- INFLAMMATORY_RESPONSE-0.430
- TNFA_SIGNALING_VIA_NFKB-0.400
- ALLOGRAFT_REJECTION-0.380
- INTERFERON_GAMMA_RESPONSE-0.380
- COMPLEMENT-0.360
- KRAS_SIGNALING_UP-0.350
- XENOBIOTIC_METABOLISM-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030948_D1.RNA-Seq | EPN | EPN Tumor | 0.890 |
| 2 | SRR1797243 | — | cohortSC | 0.886 |
| 3 | MNG239 | — | — | 0.878 |
| 4 | BS_K74PZET7 | Med | Medulloblastoma | 0.875 |
| 5 | MNG87 | — | — | 0.874 |
| 6 | BS_QXKRN6CR | Supratentorial Ependymoma | — | 0.870 |
| 7 | SRR5088890 | — | — | 0.869 |
| 8 | BS_VJVDJABP | Embryonal tumors | — | 0.867 |
| 9 | BS_VJ2S5DVS | Ependymoma NOS | — | 0.866 |
| 10 | R6 | — | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |